Background--Transplantation of adventitial pericytes (APCs) promotes cardiac repair in murine models of myocardial infarction. The aim of present study was to confirm the benefit of APC therapy in a large animal model.
C oronary artery disease is the leading cause of death worldwide, accounting for over 17 million deaths annually. Ischemic heart failure has reached epidemic proportions, accounting for an estimated 26 million people worldwide and resulting in more than 1 million hospital episodes annually in the United States and Europe. 1 Transplantation of proangiogenic cells following an acute myocardial infarction (MI) may help prevent the infarct extension by promoting cardiomyocyte rescue, awakening the hibernated myocardium in the area at risk, and modulating inflammation and fibrosis. 2, 3 Cell therapy of coronary artery disease has evolved rapidly from bench to bedside; however, despite positive results in murine models of MI, small-or medium-sized clinical studies and meta-analyses have only shown modest benefit in humans. [4] [5] [6] [7] This could be principally because of the use of inappropriate and ill-defined cell populations, which calls for a continued search for optimal, quality-assured cell products. Moreover, very few studies have adopted the robust approach to forecasting clinical efficacy through validation in both small and large animal MI models before moving to humans. 8 Different mesenchymal cell populations have been isolated from the adventitial layer of murine and human vessels. [9] [10] [11] [12] [13] [14] [15] In a seminal study, we discovered the presence of CD133 + / CD34 + /KDR + cells endowed with potent vasculogenic activity in the human fetal aorta. 14 Searching for a similar angiogenic cell population in the human adult vasculature, we have focused on adventitial pericytes (APCs) that coexpress in situ the classical markers NG2 and PDGFRb and the cell surface glycoprotein CD34. Using a Good Manufacturing Practicecompliant standard operating protocol (SOP), which consists of an initial immunosorting for the CD34 antigen and exclusion of CD31 + cells followed by adhesive culture/ expansion in a selective culture media, we were able to expand millions of viable human APCs (hAPCs) from a small remnant of the saphenous vein used for coronary artery bypass graft surgery. Expanded hAPCs share properties with mesenchymal stem cells, including the expression of CD44, CD90, CD105, and CD73, the lack of hematopoietic (CD45) and endothelial markers (CD31, von Willebrand factor, and Vascular Endothelial-cadherin), as well as clonogenicity, and immunomodulatory activity. In a series of studies conducted in mice, we demonstrated that cell therapy with hAPCs has a remarkable therapeutic potential for the treatment of peripheral and myocardial ischemia. 9, [16] [17] [18] In particular, transplantation of hAPCs promotes cardiac repair in immunodeficient and immunocompetent murine models of MI, through incorporation into the host's vasculature and the release of angiocrine and antifibrotic factors. 9, 16, 17 Haplotype analysis and cytotoxicity assays confirmed tolerance of hAPCs by the mouse immune system. 16 We have also conducted comparative studies in mice with MI, where hAPCs were shown to be superior to cKit+ cardiac stem cells in terms of proangiogenic activity. They also surpassed bone marrow-derived mesenchymal stromal cells in improving contractility indices and not causing calcification, which was frequently observed in mesenchymal stromal cells-transplanted hearts. 9, 16 In the attempt to make a further step towards clinical translation, here we report the findings of the first-ever large animal trial of xenogeneic and allogeneic APC therapy in a swine model of reperfused MI.
Materials and Methods
An extended version with details of experimental procedures is provided in Data S1. The data, analytic methods, and study materials will be made available upon request to other researchers for purposes of reproducing the results or replicating the procedure.
Ethics
Institutional Review Board approval was obtained according to the guidelines noted in the Instructions to Authors. The collection of long saphenous vein leftovers from coronary artery bypass graft surgery complied with the principles stated in the Declaration of Helsinki and was approved by the Bath Research Ethics Committee (REC reference 06/Q2001/ 197). Patients gave written informed consent for inclusion in the study. Available clinical data of vein donors together with specific use of corresponding hAPC lines are shown in Table 1 .
The in vivo studies on swine were conducted in accordance with institutional guidelines and the Guide for the Care and Use of Laboratory Animals (the Institute of Laboratory Animal
Clinical Perspective
What Is New?
• Pericytes are a promising cell product for cardiovascular repair but experimental evidence of safety and efficacy has been obtained in murine models only.
• This is the first cell therapy study of human and swine pericytes in a large animal model of reperfused myocardial infarction.
• Results show safety of the cell product. Pericyte transplantation induces proangiogenic and antifibrotic benefits, though these effects were not enough to result in functional improvements as assessed by magnetic resonance imaging.
What Are the Clinical Implications?
• Triangulation of present data and previous studies in mice suggest that pericyte therapy might be especially amenable to patients with nonrevascularizable coronary artery disease unresponsive to optimal treatment.
• Since pericytes improve angiogenesis and inhibit fibrosis, conjoint cardiomyogenic treatments may be necessary to achieve full restoration of both perfusion and contractile function. Resources, 1996) . In particular, experimental protocols received the approval of the UK Home Office (licences 30/ 3019 and I7A007F1C), the Centro National de Investigaciones Cardiovasculares Carlos III (CNIC) Institutional Animal Research Committee (CNIC 05/13), and the Regional Animal Research Committee (PROEX 51/13). Also, the report of research data from animal experiments follows the guidelines of the ARRIVE (Animals in Research: Reporting In Vivo Experiments) consensus document. 19 
APC Processing

Preparation of hAPCs
The Good Manufacturing Practice-compliant SOP for isolation/expansion of hAPCs has been described previously. 9 A new investigation was conducted to verify the genetic stability of expanded cell lines. To this aim, we performed (1) chromosome analyses of G-banded metaphases in hAPCs at the earliest possible passage (P2) and at P6/7 (which is the expansion stage providing sufficient cells for transplantation, without causing replicative senescence) 18 and (2) microarray comparative genomic hybridization of DNA extracted from vein tissue against DNA extracted from P7 hAPCs.
Preparation of sAPCs
Large-White swine (age 3-4 months) were terminally anesthetized for the collection of peripheral blood (through a jugular vein cannula) and saphenous veins. The vein was processed using a modification of the hAPC-SOP, by growing single cell suspensions of immunomagnetically sorted CD31 À CD34 + cells onto culture dishes coated with 1% porcine gelatin (Sigma-Aldrich, UK) containing Endothelial Cell Growth medium-2 (Lonza, UK) supplemented with 10% porcine serum. Adherent APC colonies appeared after 7 to 10 days of culture and were passaged to new culture dishes once they reached 70% to 80% of confluence. At P2, cells were split for further expansion or generation of frozen stocks. Peripheral blood was used to isolate mononuclear cells by Istopaque-1077 solution (Sigma-Aldrich). These cells were processed along with saphenous vein single cell suspensions to verify the selectivity of the modified SOP. The list of donor swine and specific use of corresponding sAPC lines is provided in Table 2 .
Assessment of sAPC Features
A series of comparative experiments was performed to assess the purity of cells isolated from swine veins and to verify their similarity to hAPCs. Cells were studied at P5/6, using 4 biological replicates (run in triplicate) unless otherwise specified.
Antigenic characteristics
Immunofluorescence microscopy and flow cytometry analyses were performed using the procedures and antibodies described in Tables S1 and S2 .
Analysis of gene expression
Semiquantitative polymerase chain reaction was performed on cells cultured under normoxia (20% oxygen) or hypoxia (2%) and their conditioned media (CM), using a Quant Studio 6 Flex Real-Time Polymerase Chain Reaction system (Applied Biosystems). The mRNA expression level was determined using the 2 ÀDCt method. The Taqman probes used in the molecular biology studies are shown in Table S3 .
Differentiation and clonogenic assays
Adipogenic and osteogenic differentiation studies were conducted as previously described. 9 In addition, single-cell cloning was performed on 2 sAPC lines at P3, using a motorized device connected to the flow cytometric sorter (Cyclone, Beckman Coulter). Sorted cells were placed into each well of a 96-well culture plate (Greiner Bio-one, UK) and cultured up to 4 weeks in endothelial cell growth medium-2 for quantification of colonies generated from a single cell.
Analysis of vascular endothelial growth factor A production
The levels of vascular endothelial growth factor A (VEGF-A) protein were determined in CM by an anti-human ELISA kit (R&D System, cat n#: DY293B). To this aim, sAPCs (N=3) were cultured in a T25 flask and exposed to normoxia or hypoxia for 48 hours in 2.5-mL serum-free, endothelial basal medium 2. In addition, a Western blot analysis was performed to detect the same protein in concentrated CM and unconditioned media (endothelial cell growth medium-2).
Network formation
The capacity of forming networks on Matrigel was assessed using sAPCs or swine pulmonary artery endothelial cells (sPAECs) alone or both in coculture (N=3 biological replicates run in triplicate). In addition, the network formation capacity of sPAECs was assessed following stimulation with sAPC CM or unconditioned media (endothelial cell growth medium-2).
Immunogenic Activity of APCs
Studies were carried out to compare the capacity of xenogeneic hAPCs and allogeneic sAPCs (N=3 biological replicates) to induce immune responses upon challenge with swine spleen T lymphocytes.
In Vivo Transplantation of APCs
Study design
Experiments were performed in a total of 42 female LargeWhite swine. A feasibility/efficacy study was conducted in 32 swine according to the protocol summarized in Figure 1A . In brief, reperfused MI was induced at day 0 (vide infra). A cardiac magnetic resonance (CMR) scan was performed 5 days after MI induction, immediately before randomization to intramyocardial injection of vehicle, hAPCs, or sAPCs. A follow-up CMR scan was performed at 45 days. Immediately after the last CMR scan, animals were euthanized and myocardial tissue samples from the infarct, peri-infarct, and remote areas were collected for histology, immunohistochemistry, and molecular biology studies.
An additional study was conducted to assess the engraftment of transplanted cells Figure 1B . Eight swine underwent the MI protocol and were then randomized to receive an intramyocardial injection of vehicle or hAPCs. Hearts were collected from animals euthanized at day 10 post-MI (5 days after vehicle or cell injection) for immunohistochemical assessment of cells expressing the human nuclear antigen and quantitation of human DNA using Alu Element-Based Polymerase Chain Reaction. 20 Human and swine GAPDH primers were used as housekeeping genes. Additionally, DNA from cultured hAPCs and swine vascular cells was used as positive and negative controls, respectively. In a separate experiment, 2 additional swine underwent the same MI protocol and then received an intramyocardial injection of sAPCs, which were labeled 1 day in advance with the longterm cell tracker CellTrackerTM CM-DiI (Life Technologies, C700). Briefly, CM-DiI was diluted 1:1000 in PBS and incubated with confluent cells (adherent to the culture plate) for 5 minutes at 37°C and then at 4°C for an additional 15 minutes, in the dark. Cells were then washed with PBS, fed with fresh media, and placed in the incubator overnight until injection.
MI Procedure
The protocol to induce acute MI has been described elsewhere. 21, 22 Briefly, the left anterior descending coronary artery, immediately distal to the origin of the first diagonal branch, was occluded for 50 minutes with an angioplasty balloon introduced via the percutaneous femoral route using 
CMR Protocol and Analysis
All CMR studies were performed with patients under anesthesia, maintained by continuous intravenous infusion of midazolam, in a 3-T Achieva Tx whole-body scanner (Philips Healthcare, Best, The Netherlands) equipped with a 32-element phased-array cardiac coil. The protocol included (1) a standard segmented cine steady-state free-precession sequence to provide high-quality anatomical references and to determine left ventricular enddiastolic wall thickness (EDWT), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), and left ventricular ejection fraction (LVEF); (2) a late gadoliniumenhanced sequence to assess infarct size; and (3) a dynamic acquisition with dual-saturation technique during gadoliniumbased contrast administration to determine absolute myocardial perfusion. 23, 24 CMR images were processed with a commercial analysis software (QMass MR 7.5 Medis, Leiden, the Netherlands and MR Extended Work Space 2.6, Philips Healthcare) and were analyzed by 2 independent blinded experienced investigators as previously described. Table 3 . The efficacy and engraftment studies using sAPCs used the fixed dose of 10910 6 cells ( Table 4 ). The rationale for the variable dose of hAPCs is that cell expansion from different veins yield a different number of cells at P6/7, which is largely dependent on the size of the vein leftover. In the case of sAPCs, we used a dose similar to the median injected dose of 10 swine studies reported in a recent meta-analysis. 8 Immediately after cell injection, the thoracotomy was closed, and animals were extubated and sent to the recovery room. During their recovery, animals were cared for by dedicated veterinarians and technicians at the CNIC. All animals enrolled in the efficacy studies were returned to the farm before final follow-up CMR and euthanasia.
23-25
APC Transplantation
Histological and Immunohistochemistry of Swine Hearts
After a general histological assessment to exclude the presence of tumors or calcification, analyses of microvascular density and fibrosis in peri-infarct and remote zones were carried out by 2 examiners blind to the treatment allocation, according to methods described previously. 16, 17 Quantitative data from the 2 independent assessments were then averaged and subjected to statistical analyses. Capillaries and arterioles were calculated in 40 fields (at 9200 magnification) in different segments of the myocardium, and the final data were expressed as the number of capillaries or arterioles per mm 2 .
Cardiomyocyte hypertrophy was evaluated by measuring the cell cross-sectional area in both the ventricular border and remote zones of animals, which received sAPCs or vehicle. After performing antigen retrieval using Citrate Buffer 0.01 mol/L pH=6, for 30 minutes at 98°C, 5-lm-thick sections were incubated with Alexa Fluor 488-conjugated anti-Wheat Germ Agglutinin (Invitrogen, UK, 1:100, 30 minutes RT), followed by a mouse monoclonal anti-a-sarcomeric actin primary antibody (Sigma, UK, 1:200, 2 hours 37°C) and a TRITC-conjugated goat-anti mouse IgM secondary antibody (Invitrogen, UK, 1:200, 1 hour Room temperature (RT)). Nuclei were labeled with 4 0 ,6-diamidino-2-phenylindole. Sections were analyzed at 9400 magnification. Images were taken in 1 or 2 sections per sample in areas in which cardiomyocytes were transversally cut. For each sample, cross-sectional area was measured in 100 cardiomyocytes, in which the nucleus was centrally located within the cell. Myocardial fibrosis was analyzed by Azan-Mallory staining followed by morphometric analysis using ImageJ software. 16 The data were expressed as the percentage of the fibrotic area over the total myocardial area.
In the engraftment studies, the abundance of hAPCs in the peri-infarct zone was assessed by immunostaining for the human nuclear antigen. We included sections of human hearts as a positive control to make sure the anti-human antibody was working properly. Immunofluorescence microscopy was used to determine the persistence and location of Dil-labeled sAPCs in different regions of swine hearts 5 days postinjection. In brief, 5-lm sections were cut and antigen retrieval was performed after deparaffinization using citrate buffer 0.02 mol/L, pH=6 for 30 minutes at 98°C. Sections were incubated with anti-isolectin GS-IB4 (Vector, UK, 1:200, overnight) followed by Alexa Flor 488 Streptavidin secondary antibody (Invitrogen, UK, 1:200, 1 hour, RT). Cardiomyocytes were stained with a mouse anti-asarcomeric actin (Sigma, UK, 1:200, 2 hours, RT) followed by Alexa Flor 649 anti-mouse secondary antibody (Invitrogen, UK, 1:200, 1 hour, RT). Nuclei were labeled with DAPI. Figure 1 . Study design. A, In the efficacy study, swine were subjected to closed-chest 50-minute balloon occlusion of the mid-LAD artery to induce acute MI. At day 5 post-MI, they underwent a comprehensive basal CMR study. Animals that did not show a transmural infarction (at least 50% of the wall thickness infarcted) were excluded. Immediately after day 5 CMR, animals were randomized to receive intramyocardial vehicle or APC injection via minithoracotomy. CMR was repeated at day 45 post-MI and hearts were harvested for histology and other tests described in the Materials and Methods section. B, A similar protocol was used to assess cell engraftment with hearts being collected 5 days after vehicle or APC injection. APC indicates adventitial pericyte; CMR, cardiac magnetic resonance; I/R, ischemia/reperfusion; LAD, left anterior descending; MI, myocardial infarction.
Sections were analyzed at 9200 magnification with a Zeiss inverted microscope.
Morphometric analyses were performed using the free software ImageJ (http://imagej.nih.gov/ij/).
Statistical Analysis
All results are presented as meanAESE or range of sample distribution. In some graphs, data are plotted as individual values, with repeated-measures matched values connected by a line. Gaussian distribution of quantitative values was assessed using the D'Agostino-Pearson omnibus K2 test. Two-group comparison analysis was performed by Student t test or Mann-Whitney test if data were not normally distributed. For comparison of multiple groups, ANOVA or Kruskal-Wallis test was performed, followed by Holm-Sidak's or Dunn's multiple comparisons test as appropriate. Correlation between variables was calculated by regression analysis. The contingency Fisher exact test was used to compare the survival rate in the 2 treatment groups. Probability values (P) <0.05 were considered significant. Graphs were generated using GraphPad Prism 6 (GraphPad Software, La Jolla, CA). Table 1 ). In the efficacy study, 2 animals died before completion of the study: 1 before randomization and 1 in the control group at day 9 post-MI. In the engraftment experiment, all animals completed the study and were euthanized at 10 days post-MI. CMR indicates cardiac magnetic resonance; hAPC, human adventitial pericytes.
Results
Antigenic Characteristics and Genetic Stability of hAPCs
Using flow cytometry and immunocytochemistry analyses, we confirmed the typical antigenic characteristics of hAPCs reported previously. 9, 16, 18 In addition, here we newly assessed the genetic integrity of expanded hAPCs by conventional karyotyping and comparative genomic hybridization arrays. Two out of 5 hAPC lines did not divide in culture sufficiently to allow chromosome analysis. In the remaining 3 lines studied, karyotyping was successful at the expected quality standard both at P2 and P6/7. Two of them showed no evidence of genetic instability. The third cell line showed a balanced rearrangement at P2 and an unrelated unbalanced rearrangement at P7 ( Figure S1 ). As the abnormality detected at P2 was not seen at P7, these are likely to represent random genetic changes occurring in culture, as seen not infrequently in cultured fibroblast cells. Consistently, the comparative genomic hybridization array results were normal and showed no evidence of the deletion detected at P7. The array quality was lower than acceptable for diagnostic testing, which is likely to be because of the quality of DNA extracted from the poorly growing cultures. However, no evidence of copy number change was detected in any region of the genome, which would be considered pathogenic in a diagnostic setting. These data provide reassurance about the biosafety of the expanded human cell product.
Efficacy Study With hAPCs
Clinical outcome
Closed-chest MI was performed in 19 female Large-White swine. The dose of cells injected in each swine is reported in Table 3 . One swine was excluded from the study randomization because of sudden death within 24 hours after ischemia/ reperfusion and another because the animal did not show transmural infarction at day 5 CMR (<50% of wall thickness was infarcted). The remaining 17 swine were randomized to intramyocardial injection of vehicle (N=8) or hAPCs (N=9) immediately after the CMR assessment at day 5 post-MI. In the control group, 1 swine died 4 days after the injection of vehicle. Thus, 16 swine (N=7 given vehicle and N=9 given hAPCs) completed the study. The overall mortality rate for this set of experiments was 11%. Contingency square analysis by Fisher exact test indicates there was no difference between the 2 groups regarding survival (2-tailed P=0.47). There was no difference in body weight or hematocrit between groups at day 5 and day 45 (Table 5) . Likewise, there was no effect of cell therapy on body weight gain from day 5 to day 45 (18.1AE1.4 kg versus 18.6AE1.4 kg in the vehicle group). Table 5 shows the relevant parameters that were measured at day 5 post-MI (before injection of vehicle or hAPCs) and day 45 post-MI as well as the related absolute changes from day 5 to day 45. Representative CMR videos are reported as Videos S1 through S4. Both groups were well balanced for basal measurements, and there was no difference between treatments at baseline and terminal assessment about the infarct size ( Figure 2A and 2B), LV volumes ( Figure 2C and 2D), and LVEF ( Figure 2E ) (all P>0.25). Likewise, no differences were detected in perfusion at day 45 in all the evaluated segments ( Figure 2F , P>0.15). Representative images of CMR perfusion maps are shown in Figure 2G .
CMR outcome
Histological outcome
General examination excluded the occurrence of malignant degeneration or calcification in hearts from the 2 treatment groups. In addition, there was no difference between treatments as far as the capillary or arteriole density end point is concerned (P>0.20 for both comparisons, Figure 3A through Table 2 ). In the efficacy study, 3 animals died before completion: 1 before randomization and 2 in the cell therapy group at day 5 (during immediate surgery recovery) and 41 post-MI. In the engraftment experiment, all animals completed the study and were euthanized at 10 days post-MI. MI indicates myocardial infarction; sAPC, swine adventitial pericytes.
3C). Importantly, hAPC therapy reduced interstitial fibrosis in the infarct border zone (À19% compared with the vehicle, P<0.01, Figure 3D and 3E), whereas the infarct scar was unaffected.
Engraftment Study With hAPCs
Eight swine underwent the MI protocol and were randomized 5 days later to intramyocardial injection of vehicle (N=5) or hAPCs (N=3). The dose of cells injected in each swine is reported in Table 3 . No casualties occurred in this set of experiments. Immunohistochemistry studies of hearts collected at day 10 post-MI did not detect human cells in any treatment group. These data were validated and confirmed by real-time polymerase chain reaction-based quantitation of human DNA. In parallel experiments, we could detect the human-specific Alu sequence in the genomic DNA mixture from hAPCs but not in the extracts of hAPC-or vehicleinjected swine hearts. Results suggest a rapid clearance of the injected xenogeneic cells, in contrast to the reportedly long-lasting persistence of hAPCs following injection into mouse infarcted hearts. 16 Immunogenic Activity of hAPCs
Our previous work in mice suggests that hAPCs are immune privileged, thereby enabling transplantation across major histocompatibility barriers. 16 Here, we verified this possibility by assessing the humoral and cell-mediated immune responses in swine. Results of 3 separate experiments showed the absence of natural antibodies against hAPCs in pre-immune porcine serum ( Figure 4A through 4D) . Additionally, we could not observe any complement activation as assessed by ELISA of complement component 3b ( Figure 4E and 4F) or complement-dependent cytotoxicity (caspase activity, data not shown). However, hAPCs triggered a strong immune reaction by swine splenocytes ( Figure 4G and 4H). In line, immunohistochemistry of swine hearts injected with hAPCs showed a 2-fold higher infiltration of CD45/CD3 lymphocytes as compared with vehicle-injected hearts (data not shown).
Isolation, Expansion, and Characterization of sAPCs
Having demonstrated that the swine is not immune tolerant to hAPCs and therefore not ideal for studying their therapeutic activity, we next evaluated whether an equivalent cell product could be obtained from swine saphenous veins. To this aim, we adapted the SOP previously used for isolation/expansion of hAPCs, with main modifications being the substitution of fetal bovine serum with swine serum and use of swine gelatin as a coating material of culture dishes. We expanded cells from 7 swine veins for this study (with a success of 100%). Cells grew quickly in culture with an average doubling time of 2.5 days, reaching %30 million at P6 in 6 to 8 weeks. Both saphenous vein-derived swine cells and hAPCs showed similar spindle-shape morphology at contrast phase microscopy ( Figure 5A ) and sizes as assessed by an image-based cytometer ( Figure 5B ). We next performed immunohistochemistry and flow cytometry studies to compare the 2 populations, using validated species-specific antibodies as indicated in Tables S1 and S2. The similarity of the 2 cell products was confirmed by immunocytochemistry analyses showing equivalent high expression of the lineage antigens NG2, PDGFRb, and vimentin ( Figure 5C ) and of the stemness markers GATA-4, sex-determining region Y-box 2 (SOX-2), and octamer-binding transcription factor 4 ( Figure 5D ). Both saphenous veinderived swine cells and hAPCs were negative for the endothelial markers CD31 and VE-cadherin, and expressed very low levels of CD146, whereas human umbilical vein endothelial cells and sPAECs (positive controls) express all the above antigens ( Figure 5E ). We also verify the expression of the T-box family transcription factor Tbx18, which is reportedly selectively expressed by microvascular pericytes and vascular smooth muscle cells in the adult mouse. 27 Results confirm that the TBX18 gene is detected by polymerase chain reaction for both cell lines (Ct value hAPCs=24.4 and Ct value sAPCs=26.6, data not shown), with the expression being confirmed at the protein level by Western blot analyses of cell lysates ( Figure 5F ).
Furthermore, flow cytometry studies indicate that, similar to hAPCs, saphenous vein-derived swine cells abundantly express the mesenchymal markers CD44, CD90, CD105, and PDGFRb but are negative for CD146, CD31, and the hematopoietic marker CD45 (Figure 6A through 6D) . Swine peripheral blood mononuclear cells and PAECs were used as positive controls (Figure 6E and 6F) . In addition, experiments were conducted to exclude the possibility that contamination of the vein extracts by circulating hematopoietic cells may compromise the purity of the cell product. To this aim, we isolated mononuclear cells from swine peripheral blood by Histpaque-1077 solution and cultured them using the abovedescribed APC-SOP, with or without initial immune-magnetic beads sorting for CD34/CD31. In both cases, no cell emerged during a 1-month-long culture, thus providing a definitive confirmation that the adopted SOP is selective. Altogether these data indicate that the expanded swine cell product is a bona fide equivalent of hAPCs.
Clonogenic and Differentiation Potential of sAPCs
Next, we attempted to confirm the equivalence on functional grounds. To investigate whether sAPCs can form clones, total cells from 2 biological replicates were sorted as single cells and cultured in 96-well plates. Two weeks later, 23% of cells from 1 sAPC line formed colonies (57 out of 240), while the other APC line gave rise to 67 colonies (27%). Of these primary colonies, 9 and 14 could be further expanded in culture.
We next exposed 3 sAPC lines to differentiation stimuli for the derivation of mesenchymal lineages. All the lines showed typical differentiation capacities, as denoted by the accumulation of fat droplets and Oil-Red-O staining in the adipogenesis assays and Alizarin Red and Alkaline phosphatase staining in the osteogenesis assays ( Figure S2 ). These results denote similarities with the reported clonogenic activity and in vitro differentiation properties of hAPCs. 9 
Proangiogenic Activity of sAPCs
One important feature of hAPCs consists of their ability to modulate angiogenesis via direct contacts with, and transfer of paracrine growth factors and microRNAs to endothelial cells. 9, 16, 28 Therefore, we next investigated whether sAPCs share similar properties by testing their capacity to promote endothelial cell network formation in a Matrigel assay. Interestingly, preliminary experiments showed that the sAPC-CM potentiates the network-forming capacity of human umbilical vein endothelial cells, whereas the direct contact of sAPCs and human umbilical vein endothelial cells in coculture inhibits the network formation (data not shown). This suggests that the physical interaction between cocultured xenogeneic cells can override the proangiogenic activity of the sAPC secretome. To exclude any species-specific incompatibility that may confound the interpretation of results, we next used swine endothelial cells (ie, sPAECs) as an angiogenic target for sAPCs. In this setup, both sAPCs ( Figure 7A ) and their CM ( Figure 7B ) led to potentiation of the networkforming capacity of sPAECs. Moreover, the sAPC secretome exhibited superior proangiogenic activity as compared with the hAPC secretome ( Figure 7B ), with this difference being compatible with a higher specificity of the sAPC-derived paracrine factors for sPAECs.
Angiocrine Properties of sAPCs
Our previous studies showed that hAPCs express and secrete a spectrum of angiogenic factors and microRNAs. 9, 16, 17 Likewise, as shown in Figure 7C and 7D, sAPCs express and secrete VEGF-A and the proangiogenic miR-132. They also express the hypoxia-inducible miR-210, with levels being increased in response to hypoxia ( Figure 7C ).
Immunogenic Activity of sAPCs
We performed a cytotoxic assay where sAPCs were challenged with interleukin-activated swine splenocytes. An initial assay with cells in suspension showed no cytotoxic effect. However, results were confounded by the sAPC tendency to undergo spontaneous, time-dependent apoptosis ( Figure S3 ). Therefore, we repeated the assay with cells in adhesion.
Results confirmed the compatibility between allogeneic sAPCs and effector immune swine cells (Figure 8 ).
Efficacy Study With sAPCs
Clinical outcome
Closed-chest reperfused MI was induced in 13 female LargeWhite swine. Table 4 illustrates the attribution of swine to the 2 arms of the study, the cell line code and dose, and the study outcome for each animal. One swine was excluded from the study randomization because of sudden death at day 3 after MI. The remaining 12 swine were randomized to intramyocardial injection of vehicle (N=5) or sAPCs (N=7) after the CMR assessment at day 5 post-MI. In the sAPC group, 1 swine died within a few hours after cell transplantation and another one at 1 week before the 45-day post-MI follow-up. Thus, 10 swine (N=5 given vehicle and N=5 given sAPCs) survived completing the full protocol. The overall mortality rate for this set of experiments was %23%. Contingency square analysis indicates there was no difference between the 2 groups for survival (P=0.46). Furthermore, the cumulative analysis of survival in swine given cell therapy with hAPCs and sAPCs (n=14 out of 16) or vehicle (n=12 out of 13) showed no difference between groups (2-tailed P=1.00). There was no difference in body weight or hematocrit between groups at day 5 and day 45 (Table 6 ). Likewise, there was no effect of 
CMR outcome
Similar to the human study, CMR assessment of the heart structure and function showed no difference in groups receiving sAPCs or vehicle ( Figure 9 , Table 6 and Videos S5 through S8).
Microvascular Outcomes of the Cell Therapy Studies
General examination excluded the occurrence of malignant degeneration or calcification in hearts from the 2 treatment groups. We next investigated the effect of sAPC therapy on microvascular and fibrosis outcomes. The injection of sAPCs increased the capillary density in the inferior segment of the peri-infarct zone (51%, P=0.003 versus vehicle) and the remote zone (34%, P=0.04 versus vehicle) ( Figure 10A and 10B). Arteriole density was not affected in any of the segments examined ( Figure 10C ).
Morphometric analysis of myocardial fibrosis in the infarct border zone indicates a beneficial effect of sAPC therapy (À26% reduction versus vehicle, Figure 10D and 10E). The amount of myocardial fibrosis was inversely correlated with capillary density in the whole population of injected swine with vehicle or sAPCs ( Figure 10F ).
In addition, the assessment of cardiomyocyte remodeling by calculation of the myocyte cross-sectional area denoted no difference between groups (Figure 11 ).
Engraftment of sAPCs
Two swine underwent the MI protocol and were injected 5 days later with sAPCs. The dose of cells injected in each swine is reported in Table 4 . No casualties occurred in this experiment. Immunohistochemistry of hearts collected at 5 days posttransplantation indicates the presence of DiI-labeled swine cells in the infarct and peri-infarct border zone, with a few of them surrounding the isolectin-positive vascular profiles and others dispersed in the scar ( Figure 12A ). No signal from injected swine cells was detected in the remote zone ( Figure 12B ). As expected, controls hearts injected with vehicle did not show any staining for the labeling tracer ( Figure 12C ). There was no evidence for the differentiation of injected cells into cardiomyocytes. The observed engraftment is in line with Figure 5 . Continued our previous study in mice, where Dil-labeled hAPCs were found located in the infarct and infarct border zone. 16 
Discussion
Mounting evidence from qualitative and quantitative research indicates that the triangulation of results from different models, sources, and methodologies can help achieve a deeper understanding of complex phenomena and synergize the trustworthiness and translatability of a scientific account. 29, 30 Nevertheless, neither the US Food and Drug Administration nor the European Medicine Agency have yet provided clear guidelines on whether cell therapy should be tested in 1 or more animal species and, in the latter case, how the nature and importance of data from different models should be weighed before a clinical trial can begin. Furthermore, an interesting and yet unresolved controversy surrounds the preclinical choice of using human cells, which represent the final therapeutic product but carry the problem of being xenogeneic, or the corresponding animal products, which may better simulate the current allogeneic/autologous approach of clinical cell therapy.
In an attempt to resolve these fundamental issues, here, we report the first-ever study of human and swine APC therapy in a large animal model of acute reperfused MI. The internal validity of our investigation was ensured at several key levels, with the randomized treatment groups being properly balanced for basal measurements, receiving identical care and assessment, and having similarly low levels of participant loss at final follow-up. Furthermore, we used the ARRIVE consensus checklist to certify the proper and complete reporting of research data. 15 Results obtained in swine were critically compared with previous studies conducted by us in mice (Table 7) , to draw more definitive conclusions about the safety and efficacy of this new cell therapy product. Genomic stability has a crucial role in cell-based therapies. Aneuploidy was observed in in vitro-cultured bone marrowderived mesenchymal stromal cells and adipose tissuederived mesenchymal stromal cells during culture expansion, although cells with genomic alterations do not necessarily undergo malignant transformation. [31] [32] [33] By using both traditional karyotyping and array-based comparative genomic hybridization, we demonstrate that hAPC expansion does not result in significant mutations within the genome, thus providing novel reassurance on the safety of the cell product.
On the other hand, in vitro cytotoxicity experiments and in vivo engraftment studies indicate rejection of hAPCs, because of xenogeneic antigen recognition by swine T cells. These new data contrast with the apparent tolerance of hAPCs by the murine immune system. 9, 16 Although fundamental immunological mechanisms have strong similarities among mammalians, environmental and pathogen pressure Figure 6 . Continued have led immune systems of swine and mice to markedly diverge from each other, such that results obtained in 1 species are not always transferable to another. 34 We observed a second layer of species incompatibility when performing coculture of sAPCs and human endothelial cells, which unexpectedly resulted in inhibition of in vitro network formation by the latter. Because of the translational hurdles of the xenogeneic strategy, we successfully adopted the alternative strategy of obtaining pericytes from swine veins through a slightly modified version of the human isolation protocol. The swine cell product showed close similarities with hAPCs as assessed by immunocytochemistry, flow cytometry, and functional assays. This proxy cell product represents an invaluable material, considering the increasing popularity of swine as a translational research model and potential cell/organ donor.
Importantly, the in vitro cytotoxicity assays and in vivo engraftment studies showed that transplantation of allogeneic sAPCs in the swine heart is feasible and immunologically acceptable. Moreover, the safety of the proposed cell therapy product was confirmed by visual examination of animal conditions and behavior and measurement of body weight, hematocrit, and gross pathology of the heart. Quantification of cell engraftment by immunosorting, a method we + P<0.05 vs hAPC-CM. C, Bar graphs shows the expression of VEGF-A (i), miR-210 (ii), and miR-132 (iii) in sAPC lysate under normoxia and following stimulation by hypoxia. D, VEGF-A (i) and miR-132 (iii) were also found in conditioned media and increased following hypoxia. Western blot image displaying secreted VEGF-A (MW=22 kDa) and also larger bands under normoxia condition (ii). The antibody detection of these bands suggests that either multiple molecules are bound together in a multimerized complex or that VEGF-A is bound to another molecule with the region bound by the antibody exposed/separate from the region bound by the corresponding molecule/receptor. Values are meansAESEM. **P<0.01 vs normoxia. CM indicates conditioned medium; Dil, 1,1 0 -Dioctadecyl-3,3,3 0 ,3 0 -Tetramethylindocarbocyanine; hAPCs, human adventitial pericytes; miR, microRNA; MW, molecular weight; sAPCs, swine adventitial pericytes; sPAECs, swine pulmonary artery endothelial cells; VEGF-A, vascular endothelial growth factor A. Journal of the American Heart Association successfully adopted in mice, 18 is challenging in large animals such as swine, because of the difficulties in accurately retrieving a relatively low number of injected cells from the resident cell population, which is estimated to be in the range of 10 billion cells. Imaging analyses have the potential to provide semiquantitative information noninvasively, but available methods for assessing cell engraftment still have limitations. 35 In the present study, the presence of transplanted sAPCs was confirmed by immunohistochemistry after 10 days postinfarction and 5 days from cell injection, whereas the clinical benefits were studied after 45 days. Therefore, it is not possible to know how long the transplanted cells persisted in the myocardium. These aspects represent a limitation of our investigation. With regard to efficacy, the present study was consistent with our previous publications showing a benefit in microvascular angiogenesis and interstitial fibrosis. 16, 17 Neovascularization and collagen deposition in the uninjured myocardium are important determinants of the healing response to an acute MI. Therefore, the ability of APCs to impact on these 2 parameters has considerable clinical value. When considering underpinning mechanisms, the present study recapitulates our previous results showing the APC inability to differentiate into endothelial cell or cardiomyocyte lineages. 18 Paracrine mechanisms play a key role in the proangiogenic action of cell therapy, 36 and we previously demonstrated the validity of this concept by gene silencing of angiogenic pathways in pericytes. 16, 37 For instance, hAPCs express and release proangiogenic and antifibrotic factors, such as VEGF-A, leptin, and miR-132, with the secretion of both being increased after hypoxia. 9, 16, 37 Western blot analysis showed that the VEGF-A contained in the sAPC-CM corresponds to the mature 22-kDa protein. This was also accompanied by larger VEGF-A bands. The antibody detection of these bands suggests that multiple molecules are bound together in a multimerized complex.
Alternatively, VEGF-A may be bound to another molecule, such as secreted VEGF receptors, with the region bound by the antibody exposed/separate from the region bound by the corresponding molecule/receptor. Both possibilities are supported by published evidence.
38,39 Swine and murine studies were also concordant in excluding an effect of APCs on the infarct size as determined by CMR and morphometry, respectively. On the other hand, the present swine study does not replicate the positive outcomes on cardiac function observed previously in mice. 16, 17 controversial. Two recent meta-analyses of bone marrow cell therapy trials in patients with acute MI indicate that patients experienced similar improvement in LVEF regardless of the baseline LVEF. However, improvements in left ventricular endsystolic volume were more pronounced in patients with lower baseline LVEF. 26, 40 In contrast, in trials of chronic myocardial ischemia, the increase in LVEF elicited by cell therapy was significant only in the group with lower LVEF at baseline. 40 Therefore, the lack of contractility benefit by APC therapy in swine may be related to the mild impact of reperfused MI on LVEF.
Another important difference of this large animal study consists of having assessed functional outcomes at 1 single follow-up time point. Sequential and more prolonged evaluation of cardiac function might help to interpret the discrepancies between CRM and anatomical outcomes. For instance, myocardial perfusion as determined by CMR was not improved in the animals injected with sAPCs despite an increase of capillary density observed in histology. We believe this might be the consequence of several factors. Firstly, myocardial perfusion, as well as other in vivo functional and hemodynamic parameters, might be influenced by anesthesia with additional potential inter-and intraindividual variations in experimental models. Secondly, we did not perform pharmacological stress tests, which might help to enhance the sensitivity of the perfusion assessment. Thirdly, newly formed microvessels might need a longer time to achieve optimal functional capacity. An increase in capillaries rather than arterioles was observed by histology. Arterioles are well known to be mainly responsible for the regulation of tissue blood flow; therefore it might be the case that CMR was not able to detect subtle changes in myocardial perfusion. Finally, the beneficial effect of an enhanced capillary bed on cardiomyocyte survival may have been blunted by microvascular vasoconstriction. Recent investigation indicates that pericyte constriction contributes to coronary no-reflow after postischemic reperfusion of the cardiac microcirculation. 41 It would be of paramount importance to investigate whether APC transplantation impacts on postreperfusion microvascular constriction directly or through paracrine mechanisms and if, conversely, pharmacological control of coronary microvascular constriction may enhance the restorative action of APC therapy. Another key factor to consider is the cell dose and, with regard to the hAPC transplantation study, the age of the cell donors. A meta-analysis of 10 cell therapy studies in large animal models reports a median injected dose (12910 6 cells), which is similar to the doses used in our study. 8 Our previous investigation in mice included a dose titration experiment showing that intramyocardial transplantation of 3910 5 hAPCs is sufficient to achieve significant therapeutic effects. 16 In swine, we injected hAPCs and sAPCs at 53-to 93-fold (16-28910 6 ) and 33-fold (10910 6 ) higher concentrations, respectively. Since the swine heart is %1000 times heavier than the mouse heart, these doses might be therapeutically suboptimal. It should also be noted that despite injected doses of human cells being greater than the dose elected for swine cell studies, the latter exerted superior therapeutic effects. It is likely that the majority of the human cells were lost because of the immune response of the recipient. Additionally, they may have caused other inadvertent adverse phenomena attributable to their xenogeneic nature. Aging causes a decline in the function and regenerative capacity of human cells. 42 Human donors of the present swine study were older than those recruited in the mouse study (73AE3 years versus 57AE6 years, respectively). 17 Therefore, the advanced age of the donors, in addition to the host reaction to these cells, might have contributed to the failure of hAPCs to exert the benefits seen in murine studies 12, 13 as well as in swine studies where allogeneic sAPCs were sourced from young donor animals. 
Conclusion
In summary, the results from this preclinical study support the feasibility and safety of intramyocardially injected APCs for the treatment of MI. The impact on efficacy appears confined to an improvement of vascularization and reduction of fibrosis, which was still not enough to improve function and contractile indices. When comparing this finding with the previous observation that contractility is improved in mice with nonreperfused acute MI, 16 we speculate that APC therapy might be especially amenable to patients with nonrevascularizable coronary artery disease. The majority of these patients have refractory angina, which is unresponsive to optimal treatment and associated with a markedly impaired quality of life. Our proof of concept study was conducted to assess the safety and therapeutic value of pericytes as a monotherapy. It would be of paramount importance to test pericytes in combination with optimal drug therapy for MI. Another attractive possibility is the association with other dedicated approaches of regenerative medicine. Conjoint cardiomyogenic treatments, for instance, using combinatory transplantation of cardiac stem cells as shown by us previously 17 -exosomes and vesicles secreted by cardiac stem cells 43, 44 or exogenous administration of selected mitosisrelated genes or microRNAs [45] [46] [47] [48] -may result in synergistic benefit with the restoration of microvascular perfusion and contractile function. Finally, triangulation with data from our studies in mice provides an invaluable method to interpret the experimental results, but also calls for more standard reporting guidelines for animal studies in cardiac regeneration.
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